About Lassen Therapeutics

Lassen Therapeutics develops fully human monoclonal antibodies targeting the interleukin-11 receptor to treat fibrotic diseases such as thyroid eye disease and idiopathic pulmonary fibrosis. Their approach aims to inhibit IL-11 signaling, addressing the underlying mechanisms of fibrosis to improve patient outcomes.

```xml <problem> Fibrotic diseases, such as thyroid eye disease (TED) and idiopathic pulmonary fibrosis (IPF), lead to significant morbidity and mortality. Current treatments often fail to address the underlying mechanisms driving fibrosis, resulting in limited efficacy and suboptimal patient outcomes. </problem> <solution> Lassen Therapeutics is developing fully human monoclonal antibodies that target the interleukin-11 receptor (IL-11R) to treat fibrotic diseases. Their lead program, LASN01, inhibits IL-11 signaling, a central mediator of fibrosis, thereby addressing the root cause of these diseases. By blocking the IL-11 pathway, Lassen's approach aims to prevent and reverse fibrosis, offering a potential new therapeutic option for patients with TED and IPF. The company is also developing LASN500, with ongoing Investigational New Drug (IND) enabling studies. </solution> <features> - Fully human monoclonal antibodies with high affinity and specificity for IL-11R - LASN01: Clinical-stage antibody currently in Phase 2 study for thyroid eye disease (TED) - LASN500: Antibody in Investigational New Drug (IND) enabling studies - Designed to potently block IL-11 signaling and prevent IL-11 driven fibrotic diseases </features> <target_audience> The primary target audience includes patients suffering from fibrotic diseases such as thyroid eye disease (TED) and idiopathic pulmonary fibrosis (IPF). </target_audience> ```

What does Lassen Therapeutics do?

Where is Lassen Therapeutics located?

Lassen Therapeutics is based in San Diego, United States.

When was Lassen Therapeutics founded?

Lassen Therapeutics was founded in 2018.

How much funding has Lassen Therapeutics raised?

Lassen Therapeutics has raised 117000000.

Location

San Diego, United States

Founded

2018

Funding

117000000

Employees

29 employees

Major Investors

Frazier Life Sciences, Longitude Capital

Find Investable Startups and Competitors

Search thousands of startups using natural language

AI voice (2021+)underground pipe robots energy flexibility software

Start Searching

Lassen Therapeutics

⚠️ AI-generated overview based on web search data – may contain errors, please verify information yourself! You can claim this account with your email domain to make edits.

Executive Summary

lassentherapeutics.com 3K+

Crunchbase

Founded 2018 – San Diego, United States

Funding

Estimated Funding

$100M+

Major Investors

Frazier Life Sciences, Longitude Capital

Team (25+)

No team information available.

Company Description

Problem

Fibrotic diseases, such as thyroid eye disease (TED) and idiopathic pulmonary fibrosis (IPF), lead to significant morbidity and mortality. Current treatments often fail to address the underlying mechanisms driving fibrosis, resulting in limited efficacy and suboptimal patient outcomes.

Solution

Lassen Therapeutics is developing fully human monoclonal antibodies that target the interleukin-11 receptor (IL-11R) to treat fibrotic diseases. Their lead program, LASN01, inhibits IL-11 signaling, a central mediator of fibrosis, thereby addressing the root cause of these diseases. By blocking the IL-11 pathway, Lassen's approach aims to prevent and reverse fibrosis, offering a potential new therapeutic option for patients with TED and IPF. The company is also developing LASN500, with ongoing Investigational New Drug (IND) enabling studies.

Features

Fully human monoclonal antibodies with high affinity and specificity for IL-11R

LASN01: Clinical-stage antibody currently in Phase 2 study for thyroid eye disease (TED)

LASN500: Antibody in Investigational New Drug (IND) enabling studies

Designed to potently block IL-11 signaling and prevent IL-11 driven fibrotic diseases

Target Audience

The primary target audience includes patients suffering from fibrotic diseases such as thyroid eye disease (TED) and idiopathic pulmonary fibrosis (IPF).